Immuron (NASDAQ:IMRN) Sees Large Decline in Short Interest

Immuron (NASDAQ:IMRN) was the recipient of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 61,753 shares, a drop of 46.6% from the September 15th total of 115,685 shares. Based on an average trading volume of 109,695 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.8% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immuron in a research report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, Immuron has a consensus rating of “Sell”.

Immuron Stock Performance

Shares of IMRN stock remained flat at $1.03 during midday trading on Thursday. 26,406 shares of the company’s stock were exchanged, compared to its average volume of 759,306. The business has a 50 day simple moving average of $1.21 and a 200 day simple moving average of $1.10. Immuron has a one year low of $0.68 and a one year high of $2.39.

Immuron (NASDAQ:IMRN) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $1.27 million for the quarter.

Immuron Company Profile

Immuron Limited (NASDAQ:IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered immunotherapies. Its products are based primarily on antibodies derived from hyperimmune bovine colostrum and are designed to act locally in the gastrointestinal tract rather than enter the bloodstream.

The company’s leading product is Travelan, an oral treatment intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC).